EV295/#637 Cri-cctg-0003/ind240 an immunotherapy platform study (IPROC) in platinum-resistant high grade serous ovarian cancer (PltnR-HGSC): substudies a/b: durvalumab + BA3011 or BA3021.(nct04918186)
Helen Mackay,Anna V. Tinker,Brad H. Nelson,Dmitriy Zamarin,O. O. Adekunle,Stephanie Lheureux,Ellard Susan,Alannah Smrke,Pierre Olivier Gaudreau,Tess Faulkner,Wei Tu,Janet Dancey